The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies compared to natural history external control are muscular enough to get the process going without having to dive into additional studies.
Lee Landenberger is a Staff Writer for Bioworld co., focusing on the biotechnology and pharmaceutical industries. With a keen interest in innovation and breakthroughs in the field, Lee covers a wide range of topics including clinical trials, drug development, collaborations, and market trends.